Ongoing Assessments & Recent Research.
Easy access to our work
Alzheimer’s Disease
Jul 2021Atopic Dermatitis
Jul 2021Hereditary Angioedema
Jul 2021Hypertrophic Cardiomyopathy
Oct 2021Lupus Nephritis
Mar 2021Multiple Myeloma
Apr 2021Myasthenia Gravis
Sep 2021Featured News & Insights.
Learn about our latest work.
ICER Publishes Final Evidence Report and Policy Recommendations on Therapies for Lupus Nephritis
— For belimumab and voclosporin, independent appraisal committee votes highlight the importance of several potential benefits of both treatments for patients and families beyond health improvement. —
04/16/2021ICER to Use Aetion Observational RWE to Update Value Assessment of Treatments for Hereditary Angioedema
New ICER pilot will incorporate more than 24 months of observational real-world demographic, utilization, and cost data to further clarify therapies’ value. Through continued use of the Aetion Evidence Platform, ICER advances the use of transparent, replicable real-world evidence in health technology assessment.
04/12/2021ICER to Assess Treatment for Hypertrophic Cardiomyopathy
Report will be subject of CTAF meeting in October 2021; Draft Scoping Document open to public comment until April 29th, 2021
04/08/2021The ICER Impact.
New York Medicaid pursued discounts, many of which were in line with ICER reports, which have saved the state over $300 million
Engaged with over 300 patient groups and patient reps
In a landmark international program, HTA agencies around the world can now access ICER’s customizable COVID-19 Cost-Effectiveness Model
Current
Policy Papers.
Easy access to our ongoing policy papers
Unsupported Price Increases
Out of 10 identified drugs that had substantial 2019 price increases on top of already high current spending, seven were not supported by new clinical evidence; the net price increases on these seven drugs alone cost Americans an additional $1.2 billion in annual drug spend.
Alternative Policies for Pricing Novel Vaccines and Drug Therapies for COVID-19
This white paper provides a brief overview of approaches to manage the pricing of novel vaccines and treatments in times of public health emergencies.
Cornerstones of ‘Fair’ Drug Coverage
Informed by expert input from patient groups, clinician specialty societies, payers, and life science companies, this white paper provides recommendations for appropriate design and implementation of policies that determine patient access to prescription drugs.
Latest
Developments.
We’re hiring! Click here to see our full time job listings.
Learn more about how the patient perspective influences ICER’s work, and learn how you can be involved.
Listen to our podcast, “A Prescription for Fair Pricing“. Subscribe now on Apple, Google, or Spotify.